A Review of the Critical Role of Imaging in Primary Liver Malignancy

This program may include discussion of off-label treatments and investigational agents not approved by the FDA for use in the United States.

Primary Liver Cancer Background

Major Risk Factors for HCC

Who Should Be Screened for HCC?

Screening Recommendations for HCC

Screening Case 1 42-Year-Old Man With HBV Infection

Screening Case 1 LI-RADS® Classification US-2 Subthreshold

Screening Case 2 39-Year-Old Man With Alcohol-Related Cirrhosis

Screening Case 2 Findings US-1 Negative With Severe Limitations

Diagnostic Imaging in HCC

Use of Contrast in Liver MRI

Diagnostic Case 1: 70-Year-Old Man With HCV-Related Cirrhosis and Positive HCC Screening

LI-RADS® Classification Overview

LI-RADS® Classification Overview

LI-RADS® Classification Overview

Diagnostic Case 2: 59-Year-Old Man With Cirrhosis Caused by HBV and HCV Infection

Diagnostic Case 2 LI-RADS® Classification

Diagnostic Case 2 LI-RADS® Classification

Diagnostic Case 2 LI-RADS® Classification

Diagnostic Case 2 LI-RADS® Classification

TNM Staging for HCC

Imaging Treatment Response in HCC

LI-RADS® Guidance on Assessing Treatment Response in HCC

Treatment Response Categories

Treatment Response Case 1: 65-Year-Old Woman With HCV-Related Cirrhosis With Positive US

Treatment Response Case 1: 65-Year-Old Woman With HCV-Related Cirrhosis With Positive US (cont)

Treatment Response Case 1: 65-Year-Old Woman With HCV-Related Cirrhosis With Positive US (cont)

Embolic Treatment Response

Measurement of Viable Tumor

LI-RADS® Technical Recommendations for MRI

LI-RADS® Technical Recommendations for CT

CEUS

CEUS (cont)

Concluding Remarks

Abbreviations